51110-58-8

Basic information

• Product Name: 1,2-BENZISOXAZOLE-4-OL, 3-METHYL-
• Synonyms: 1,2-BENZISOXAZOLE-4-OL, 3-METHYL-;3-methylbenzo[d]isoxazol-4-ol;3-METHYL-1,2-BENZISOXAZOL-4-OL
• CAS NO: 51110-58-8
• Molecular Formula: C₈H₇NO₂
• Molecular Weight: 149.14668
• Mol File: 51110-58-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,2-BENZISOXAZOLE-4-OL, 3-METHYL-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-BENZISOXAZOLE-4-OL, 3-METHYL-(51110-58-8)
• EPA Substance Registry System: 1,2-BENZISOXAZOLE-4-OL, 3-METHYL-(51110-58-8)

Safety Data

• Hazardous Substances Data: 51110-58-8(Hazardous Substances Data)

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule of the compound.

Explanation

It is a heterocyclic compound that contains both benzene and isoxazole rings.

Explanation

The physical appearance of the compound in its solid state.

Explanation

It is used as an intermediate in the production of various pharmaceuticals and agrochemicals due to its unique structure.

Explanation

The compound has shown potential in exhibiting anti-inflammatory and anticancer properties, making it a subject of interest in medicinal chemistry research.

Explanation

Its unique structure makes it a valuable tool for organic synthesis, particularly in the development of new pharmaceuticals and agrochemicals.

Structure

Derivative of benzisoxazole

Appearance

White to off-white powder

Uses

Synthesis of pharmaceuticals and agrochemicals

Biological Activities

Anti-inflammatory and anticancer properties

Importance

Building block in organic synthesis

Upstream product

• 699-83-2 2,6-dihydroxylacetophenone 
• 1380697-19-7 1-(2,6-dihydroxyphenyl)ethanone O-acetyloxime 
• 22233-82-5 1-(2,6-dihydroxyphenyl)ethan-1-one oxime 

Downstream Products

• 1380697-20-0 3-methyl-4-[(4-nitrophenyl)oxy]-1,2-benzisoxazole 
• 1380697-21-1 4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]aniline 
• 1380696-11-6 (5R)-5-methyl-3-{4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl}-2,4-imidazolidinedione 
• 1380696-13-8 5,5-dimethyl-3-{4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl}-2,4-imidazolidinedione 
• 1380697-22-2 1,1-dimethylethyl [(1R)-1-methyl-2-({4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl}amino)-2-oxoethyl]carbamate 
• 1380697-23-3 N₁-{4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl}-D-alaninamide 
• 1380697-29-9 1,1-dimethylethyl [1,1-dimethyl-2-({4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl}amino)-2-oxoethyl]carbamate 
• 1380697-30-2 2-methyl-N₁-{4-[(3-methyl-1,2-benzisoxazol-4-yl)oxy]phenyl}alaninamide 
• 63152-60-3 3-Methyl-4-(3-hydroxy-3-tert.-butylamino-propoxy)-1,2-benzisoxazol 

Relevant articles and documents

Bioavailability Studies and in vitro Profiling of the Selective Excitatory Amino Acid Transporter Subtype 1 (EAAT1) Inhibitor UCPH-102

Although the selective excitatory amino acid transporter subtype 1 (EAAT1) inhibitor UCPH-101 has become a standard pharmacological tool compound for in vitro and ex vivo studies in the EAAT research field, its inability to penetrate the blood-brain barrier makes it unsuitable for in vivo studies. In the present study, per os (p.o.) administration (40 mg kg-1) of the closely related analogue UCPH-102 in rats yielded respective plasma and brain concentrations of 10.5 and 6.67 μm after 1 h. Three analogue series were designed and synthesized to improve the bioavailability profile of UCPH-102, but none displayed substantially improved properties in this respect. In vitro profiling of UCPH-102 (10 μm) at 51 central nervous system targets in radioligand binding assays strongly suggests that the compound is completely selective for EAAT1. Finally, in a rodent locomotor model, p.o. administration of UCPH-102 (20 mg kg-1) did not induce acute effects or any visible changes in behavior. EAAT1 inhibition beyond the BBB: In the present study, oral administration (40 mg kg-1) of the selective excitatory amino acid transporter subtype 1 (EAAT1) inhibitor UCPH-102 in rats yielded respective plasma and brain concentrations of 10.5 and 6.67 μm after 1 h. In vitro profiling of UCPH-102 (10 μm) at 51 central nervous system targets in radioligand binding assays strongly suggests that the compound is fully selective for EAAT1.

HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS

The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.